American Association for Cancer Research

Table 5

Association of COMT polymorphism and CYP1A1 (MspI), CYP1A1 (Ile/Val), CYP1A2, and CYP1B1 polymorphisms with the risk of ovarian cancer

Genotype	COMT–Val/Val							COMT–any Met		P^b for interaction
Genotype		Cases	Controls	OR^a	95% CI	Cases	Controls	OR^a	95% CI	P^b for interaction
CYP1A1 (MspI)
m1/m1	19	30	1^c		34	46	1.2	0.5–2.6
Any m2	31	38	1.2	0.5–2.8	37	30	2.0	0.9–4.5	0.53
CYP1A1 (Ile/Val)
A/A	33	45	1^c		57	57	1.5	0.8–2.8
Any G	18	23	1.0	0.4–2.3	15	19	1.0	0.4–2.5	0.53
CYP1A2
A/A	29	31	1^c		44	36	1.5	0.7–3.1
Any C	18	31	0.8	0.4–1.9	25	40	0.8	0.4–1.7	0.40
CYP1B1
Leu/Leu	34	48	1^c		32	47	0.9	0.5–1.8
Any Val	18	20	1.3	0.5–3.0	41	29	2.6	1.2–5.5	0.17

Genotype	COMT–Val/Val							COMT–any Met		P^b for interaction
Genotype		Cases	Controls	OR^a	95% CI	Cases	Controls	OR^a	95% CI	P^b for interaction
CYP1A1 (MspI)
m1/m1	19	30	1^c		34	46	1.2	0.5–2.6
Any m2	31	38	1.2	0.5–2.8	37	30	2.0	0.9–4.5	0.53
CYP1A1 (Ile/Val)
A/A	33	45	1^c		57	57	1.5	0.8–2.8
Any G	18	23	1.0	0.4–2.3	15	19	1.0	0.4–2.5	0.53
CYP1A2
A/A	29	31	1^c		44	36	1.5	0.7–3.1
Any C	18	31	0.8	0.4–1.9	25	40	0.8	0.4–1.7	0.40
CYP1B1
Leu/Leu	34	48	1^c		32	47	0.9	0.5–1.8
Any Val	18	20	1.3	0.5–3.0	41	29	2.6	1.2–5.5	0.17

Adjusted by multiple unconditional logistic regression for age, ethnicity, education, pregnancy history, oral contraceptive pill use, history of tubal ligation, and regularity of menstrual cycles.

Based on the likelihood ratio test comparing models with and without an interaction term.

Reference category.

View Large

This Feature Is Available To Subscribers Only